Mineralys Therapeutics Presents New Post-Hoc Analysis From Target-HTN Phase 2 Trial Of Lorundrostat In Late-Breaking Poster Session At ASN Kidney Week 2023 Meeting
Portfolio Pulse from Benzinga Newsdesk
Mineralys Therapeutics (NASDAQ:MLYS) presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a treatment for uncontrolled or treatment-resistant hypertension. The analysis supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment. The ongoing Advance-HTN trial will further characterize hypertensive endotype for enhanced response to lorundrostat treatment.
November 02, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mineralys Therapeutics' new analysis supports the potential of lorundrostat for treating obesity-associated hypertension. This could positively impact the company's stock as it indicates progress in their clinical trials.
The new analysis presented by Mineralys Therapeutics supports the potential of lorundrostat for treating obesity-associated hypertension. This indicates progress in their clinical trials, which could increase investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100